Clinical Genomics announces Asia-Pacific distributors

Biotechnology company Clinical Genomics has announced its newest distributors, expanding the reach of its colorectal cancer screening products in the Asia-Pacific region.

Pathology company Hi-Precision Diagnostics will distribute Clinical Genomics’ faecal immunochemical test, ‘Insure FIT’, in the Philippines. The test will replace the older ‘guaiac’ technology, which is being phased out of many colorectal screening programs around the world.

Clinical Genomics has also renewed an exclusive distribution deal with Green Cross Health, a provider of primary healthcare services to communities throughout New Zealand. The FIT technology is branded in New Zealand as ‘Bowelscreen Aotearoa’.

Finally, Clinical Genomics has announced an update regarding its deal with BioChain Group, which was appointed the exclusive distributor for InSure FIT in China late last year. Warren Bingham, Clinical Genomics vice-president Asia Pacific, said the company is “anticipating approval in the next few months to sell in China by the CFDA (Chinese Food and Drug Administration)”.

“These deals represent important milestones as part of the company’s expansion in the Asia-Pacific region,” Bingham said. “Our test has been clinically proven via decades of research and its adoption has demonstrated its ease of use for patients. With colorectal cancer prevention emerging as a major priority for many Asian countries, we are uniquely placed as the market for our affordable, easy-to-use and heat-stable products expands.”